Recombinant stabilized RSV B prefusion F antigen is one component of a bivalent respiratory syncytial virus (RSV) vaccine called Abrysvo. The vaccine comprises two antigens - the other being recombinant stabilized RSV A prefusion F antigen - which have been expressed in Chinese hamster ovary cell lines and then purified and lyophilized.L48066 In contrast to another RSV vaccine, respiratory syncytial virus vaccine, adjuvanted (Arexvy), Abrysvo is reconstituted with sterile water prior to injection and does not require the co-administration of an adjuvant.L48066
Abrysvo was first approved by the FDA in May 2023 for use in patients ?60 years of age, and received subsequent approval in August 2023 for use in pregnant individuals for the protection of infants through six months of age.L49555 Abrysvo was approved for the same indications in the EU in August 2023L49565 and Canada in December 2023.L49560 It is the first RSV vaccine approved for use in pregnant patients to prevent RSV in infants.L49555
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.